tailieunhanh - Báo cáo y học: "Health economic evaluations comparing insulin glargine with NPH insulin in patients with type 1 diabetes: a systematic review"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về ngành y học đề tài: Health economic evaluations comparing insulin glargine with NPH insulin in patients with type 1 diabetes: a systematic review. | Hagenmeyer et al. Cost Effectiveness and Resource Allocation 2011 9 15 http content 9 1 15 COST EFFECTIVENESS AND RESOURCE ALLOCATION REVIEW Open Access Health economic evaluations comparing insulin glargine with NPH insulin in patients with type 1 diabetes a systematic review Ernst-Gunther Hagenmeyer1 Katharina C Koltermann2t Franz-Werner Dippel3 and Peter K Schadlich4 Abstract Background Compared to conventional human basal insulin neutral protamine Hagedorn NPH the long-acting analogue insulin glargine GLA is associated with a number of advantages regarding metabolic control hypoglycaemic events and convenience. However the unit costs of GLA exceed those of NPH. This study aims to systematically review the economic evidence comparing GLA with NPH in basal-bolus treatment intensified conventional therapy ICT of type 1 diabetes in order to facilitate informed decision making in clinical practice and health policy. Methods A systematic literature search was performed for the period of January 1st 2000 to December 1st 2009 via Embase Medline the Cochrane Library the databases GMS German Medical Science and DAHTA Deutsche Agentur fur Health Technology Assessment and the abstract books of relevant international scientific congresses. Retrieved studies were reviewed based on predefined inclusion criteria methodological and quality aspects. In order to allow comparison between studies currencies were converted using purchasing power parities PPP . Results A total of 7 health economic evaluations from 4 different countries fulfilled the predefined criteria 6 modelling studies all of them cost-utility analyses and one claims data analysis with a cost-minimisation design. One cost-utility analysis showed dominance of GLA over NPH. The other 5 cost-utility analyses resulted in additional costs per quality adjusted life year QALY gained for GLA ranging from 3 859 to 57 002 incremental cost effectiveness ratio ICER . The cost-minimisation analysis